Preterm Birth and PROM Testing Market Size, Share, and Trends

Preterm Birth and PROM Testing Market Size, Share and Growth Analysis (By Test Type: Ultrasound, Biochemical Markers, Pelvic Exam, Nitazine Test, Uterine Monitoring, Pooling, Ferning Test, and Others; By End User: Diagnostic Laboratories, Hospitals, and Others) - Global Industry Analysis, Trends, Regional Outlook, and Forecast 2022 - 2030

  • Last Updated : November 2023
  • Report Code : 1281
  • Category : Healthcare

The preterm birth and PROM testing market size was valued at USD 180 billion in 2022 and is expected to hit over USD 2.21 billion by 2030 with a registered CAGR of 3.2% from 2022 to 2030.

Preterm Birth and PROM Testing Market Size 2020 to 2030

Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare

Key Takeaways

  • North America generated more than 38% of revenue share in 2022.
  • Asia-Pacific is estimated to expand at the fastest CAGR from 2023 to 2030.
  • By Test Type, the ultrasound segment has held the largest revenue share of 32% in 2022.
  • By End User, the hospitals & clinics segment contributed more than 45% of revenue share in 2022.

Growth Factors

The growing cases of preterm birth are the primary factor for the growing demand for preterm birth and PROM testing across the globe. As per the data published by the WHO, around 15 million babies are born preterm annually across the world. Preterm birth and PROM testing helps to detect the premature rapture of fetal membranes in pregnant women. By detecting the raptured fetal membrane, the patient can be treated and prevent the preterm birth. According to WHO, preterm birth is a major factor for the death of children under the age of 5 years. The rate of preterm birth ranges from 5% to 18% in across 184 countries. This rate is projected to increase further in the foreseeable future. Hence, the demand for the preterm birth and PROM testing is expected to grow at a significant pace in the upcoming years.

Another factor propelling the growth of the preterm birth and PROM testing market is the growing penetration of diagnostic labs and healthcare units especially in the emerging markets. The popularity and adoption of diagnostic centers is increasing due to higher reliability, cost-effectiveness, and faster results. In underdeveloped and emerging nations, the popularity of healthcare and diagnostic centers is increasing rapidly as they provide accurate diagnosis results at low cost. This is one of the key factors driving the growth of the preterm birth and PROM testing market.

Preterm Birth and PROM Testing Market Scope

Report Highlights Details
Market Size USD 2.21 Billion by 2030
Growth Rate CAGR of 3.2% From 2022 to 2030
Base Year 2020
Historic Data 2017 to 2020
Forecast Period 2022 to 2030
Segments Covered Test Type, End User
Regional Scope North America, APAC, Europe, Latin America, MEAN, Rest of the World
Companies Mentioned Abbott, Qiagen N.V., Biosynex, Hologic, Cooper Surgical, Sera Prognostics, Medixbiochemica, IQ Products, NX Prenatal, Inc., Clinical Innovations, Inc.

 

COVID-19 Impact

The outbreak of COVID-19 led to worldwide lockdown, thereby forcing the population to stay at home. Moreover, transportation was hampered during the lockdown period. However, the COVID-19 positively impacted the market and an upsurge was witnessed in the demand for the preterm birth and PROM testing market. According to CDC, a pregnant women infected with the COVID-19 virus is at higher risk and the chances of preterm birth rises in such condition. This rapidly surged the demand for the preterm birth and PROM testing. However, owing to the supply chain disruptions, the distribution of the PROM test solutions were hampered.

Test Type Insights

By Test Type, in 2020, the ultrasound dominated the market with around 32% share in terms of revenue of the total market.

Ultrasound is the most common type of test conducted by the doctors to observe developing fetus. Ultrasound is a simple test where sound waves are used to produce images of the fetus inside the womb. It is considered to be the safest and painless test as no needles or injections and ionizing radiations are used. Therefore, the ultrasound is projected to retain its dominance throughout the forecast period.

Preterm Birth and PROM Testing Market Share, By Test Type, 2020 (%)

On the other hand, the biomarker test is estimated to be the fastest growing during the forecast period. This is attributed to the accuracy of the biomarker test. A biomarker test is more accurate and reliable than the ultrasound testing. Moreover, biomarker tests can identify the patients that need urgent care. Further it is inexpensive, reliable, and usable at the POC (Point of Care). All these factors make the biomarker the most opportunistic segment during the forecast period.

End User Insights

By End User, in 2020, the diagnostic laboratories dominated the market with around 45% share in terms of revenue of the total market.

The growing penetration of diagnostic labs all over the globe is positively contributing towards the growth of the preterm birth and PROM testing market. The rising awareness regarding PROM test coupled with rising disposable income and technological advancements in the medical test equipment has fostered the segment growth in the past few years. Moreover, cost-effectiveness has been achieved in the field of PROM testing that drives the growth of this segment.

Preterm Birth and PROM Testing Market Share, By End User, 2020 (%)

The others segment includes healthcare units, and others point of care units. This segment is gaining rapid traction due to its increasing penetration across the globe. This segment is estimated to grow at a promising rate during the forecast period.

Regional Insights

North America dominated the preterm birth and PROM market and accounted for the largest revenue share of 38% in 2020. This is attributed to the growing cases of preterm birth rate in U.S. According to CDC (Centers for Disease Control and Prevention), 10% of the babies born in 2019 in US were born preterm. Around 17% of the preterm babies die due to low birth weight. The higher adoption of advanced technologies in the preterm birth and PROM testing has fueled the growth of the market in this region.

Preterm Birth and PROM Testing Market Share, By Region, 2020 (%)

On the other hand, Asia Pacific is expected to be the most opportunistic market throughout the forecast period. According to the WHO, over 60% of the preterm birth cases occur in Africa and South Asia. The poor families in this developing region suffer the most. However, the growing awareness regarding the availability of PROM tests is positively impacting the market growth in the Asia Pacific region.

Key Companies & Market Share Insights

The market is moderately fragmented with the presence of several local companies. These market players are striving to gain higher market share by adopting strategies, such as investments, partnerships, and acquisitions & mergers. Companies are also spending on the development of improved and efficient preterm birth and PROM testing solutions. Moreover, they are also focusing on maintaining competitive pricing.

Preterm Birth and PROM Testing Market Companies

  • Abbott
  • Qiagen N.V.
  • Biosynex
  • Hologic
  • Cooper Surgical
  • Sera Prognostics
  • Medixbiochemica
  • IQ Products
  • NX Prenatal, Inc.
  • Clinical Innovations, Inc.

Segments Covered in the Report

By Test Type

  • Ultrasound
  • Biochemical Markers
  • Pelvic Exam
  • Nitazine Test
  • Uterine Monitoring
  • Pooling
  • Ferning Test
  • Others

By End User

  • Diagnostic Laboratories
  • Hospitals
  • Others

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
  • Rest of the World

Frequently Asked Questions

According to Precedence Research, the preterm birth and PROM testing market was valued at US$ 1.61 billion in 2020 and is projected to reach US$ 2.21 billion by 2030.

The preterm birth and PROM testing market is expected to grow at a CAGR of 3.2% between 2022 to 2030.

The preterm birth and PROM testing market growth driven by rising cases of preterm birth across the world, growing penetration of diagnostic labs and healthcare centers and point of care test is gaining traction.

North America dominated the global preterm birth and PROM testing market in 2020 and projected to augment the market in the coming years.

Asia Pacific is estimated to be the most opportunistic market owing to the rising awareness regarding preterm birth.

By Test Type, in 2020, the ultrasound dominated the market with around 32% share in terms of revenue of the total market.

The major players in the preterm birth and PROM testing market are Abbott, Qiagen N.V., Biosynex, Hologic, Cooper Surgical, Sera Prognostics, Medixbiochemica, IQ Products, NX Prenatal, Inc., and Clinical Innovations, Inc..

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Preterm Birth and PROM Testing Market, By Test

7.1. Preterm Birth and PROM Testing Market, by Test Type, 2021-2030

7.1.1. Ultrasound

7.1.1.1. Market Revenue and Forecast (2017-2030)

7.1.2. Biochemical Markers

7.1.2.1. Market Revenue and Forecast (2017-2030)

7.1.3. Pelvic Exam

7.1.3.1. Market Revenue and Forecast (2017-2030)

7.1.4. Nitazine Test

7.1.4.1. Market Revenue and Forecast (2017-2030)

7.1.5. Uterine Monitoring

7.1.5.1. Market Revenue and Forecast (2017-2030)

7.1.6. Pooling

7.1.6.1. Market Revenue and Forecast (2017-2030)

7.1.7. Ferning Test

7.1.7.1. Market Revenue and Forecast (2017-2030)

7.1.8. Others

7.1.8.1. Market Revenue and Forecast (2017-2030)

Chapter 8. Global Preterm Birth and PROM Testing Market, By End User

8.1. Preterm Birth and PROM Testing Market, by End User, 2021-2030

8.1.1. Diagnostic Laboratories

8.1.1.1. Market Revenue and Forecast (2017-2030)

8.1.2. Hospitals

8.1.2.1. Market Revenue and Forecast (2017-2030)

8.1.3. Others

8.1.3.1. Market Revenue and Forecast (2017-2030)

Chapter 9. Global Preterm Birth and PROM Testing Market, Regional Estimates and Trend Forecast

9.1. North America

9.1.1. Market Revenue and Forecast, by Test (2017-2030)

9.1.2. Market Revenue and Forecast, by End User (2017-2030)

9.1.3. U.S.

9.1.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.1.3.2. Market Revenue and Forecast, by End User (2017-2030)

9.1.4. Rest of North America

9.1.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.1.4.2. Market Revenue and Forecast, by End User (2017-2030)

9.2. Europe

9.2.1. Market Revenue and Forecast, by Test (2017-2030)

9.2.2. Market Revenue and Forecast, by End User (2017-2030)

9.2.3. UK

9.2.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.2.3.2. Market Revenue and Forecast, by End User (2017-2030)

9.2.4. Germany

9.2.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.2.4.2. Market Revenue and Forecast, by End User (2017-2030)

9.2.5. France

9.2.5.1. Market Revenue and Forecast, by Test (2017-2030)

9.2.5.2. Market Revenue and Forecast, by End User (2017-2030)

9.2.6. Rest of Europe

9.2.6.1. Market Revenue and Forecast, by Test (2017-2030)

9.2.6.2. Market Revenue and Forecast, by End User (2017-2030)

9.3. APAC

9.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.3.2. Market Revenue and Forecast, by End User (2017-2030)

9.3.3. India

9.3.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.3.3.2. Market Revenue and Forecast, by End User (2017-2030)

9.3.4. China

9.3.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.3.4.2. Market Revenue and Forecast, by End User (2017-2030)

9.3.5. Japan

9.3.5.1. Market Revenue and Forecast, by Test (2017-2030)

9.3.5.2. Market Revenue and Forecast, by End User (2017-2030)

9.3.6. Rest of APAC

9.3.6.1. Market Revenue and Forecast, by Test (2017-2030)

9.3.6.2. Market Revenue and Forecast, by End User (2017-2030)

9.4. MEA

9.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.4.2. Market Revenue and Forecast, by End User (2017-2030)

9.4.3. GCC

9.4.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.4.3.2. Market Revenue and Forecast, by End User (2017-2030)

9.4.4. North Africa

9.4.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.4.4.2. Market Revenue and Forecast, by End User (2017-2030)

9.4.5. South Africa

9.4.5.1. Market Revenue and Forecast, by Test (2017-2030)

9.4.5.2. Market Revenue and Forecast, by End User (2017-2030)

9.4.6. Rest of MEA

9.4.6.1. Market Revenue and Forecast, by Test (2017-2030)

9.4.6.2. Market Revenue and Forecast, by End User (2017-2030)

9.5. Latin America

9.5.1. Market Revenue and Forecast, by Test (2017-2030)

9.5.2. Market Revenue and Forecast, by End User (2017-2030)

9.5.3. Brazil

9.5.3.1. Market Revenue and Forecast, by Test (2017-2030)

9.5.3.2. Market Revenue and Forecast, by End User (2017-2030)

9.5.4. Rest of LATAM

9.5.4.1. Market Revenue and Forecast, by Test (2017-2030)

9.5.4.2. Market Revenue and Forecast, by End User (2017-2030)

Chapter 10. Company Profiles

10.1. Abbott

10.1.1. Company Overview

10.1.2. Product Offerings

10.1.3. Financial Performance

10.1.4. Recent Initiatives

10.2. Qiagen N.V.

10.2.1. Company Overview

10.2.2. Product Offerings

10.2.3. Financial Performance

10.2.4. Recent Initiatives

10.3. Biosynex

10.3.1. Company Overview

10.3.2. Product Offerings

10.3.3. Financial Performance

10.3.4. Recent Initiatives

10.4. Hologic

10.4.1. Company Overview

10.4.2. Product Offerings

10.4.3. Financial Performance

10.4.4. Recent Initiatives

10.5. Cooper Surgical

10.5.1. Company Overview

10.5.2. Product Offerings

10.5.3. Financial Performance

10.5.4. Recent Initiatives

10.6. Sera Prognostics

10.6.1. Company Overview

10.6.2. Product Offerings

10.6.3. Financial Performance

10.6.4. Recent Initiatives

10.7. Medixbiochemica

10.7.1. Company Overview

10.7.2. Product Offerings

10.7.3. Financial Performance

10.7.4. Recent Initiatives

10.8. IQ Products

10.8.1. Company Overview

10.8.2. Product Offerings

10.8.3. Financial Performance

10.8.4. Recent Initiatives

10.9. NX Prenatal, Inc.

10.9.1. Company Overview

10.9.2. Product Offerings

10.9.3. Financial Performance

10.9.4. Recent Initiatives

10.10. Clinical Innovations, Inc.

10.10.1. Company Overview

10.10.2. Product Offerings

10.10.3. Financial Performance

10.10.4. Recent Initiatives

Chapter 11. Research Methodology

11.1. Primary Research

11.2. Secondary Research

11.3. Assumptions

Chapter 12. Appendix

12.1. About Us

12.2. Glossary of Terms

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client